VERTEX PHARMACEUTICALS INC MA
For the period ended Jun 30, 2024. Filed Aug 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 2, 2024
VRTX$547.89-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity -
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings · Total Shareholders’ Equity | ||||||
| Shares · Amount | ||||||
| Balance at March 31, 2023 | 257.5 | $2.6 | $7,220.2 | $(13.1) | $7,222.6 | $14,432.3 |
| Other comprehensive loss, net of tax | — | — | — | (26.7) | — | (26.7) |
| Net income | — | — | — | — | 915.7 | 915.7 |
| Repurchases of common stock | (0.0) | (0.0) | (25.5) | — | — | (25.5) |
| Common stock withheld for employee tax obligations | (0.0) | (0.0) | (3.1) | — | — | (3.1) |
| Issuance of common stock under benefit plans | 0.3 | 0.0 | 57.6 | — | — | 57.6 |
| Stock-based compensation expense | — | — | 119.9 | — | — | 119.9 |
| Balance at June 30, 2023 | 257.8 | $2.6 | $7,369.1 | $(39.8) | $8,138.3 | $15,470.2 |
| Balance at March 31, 2024 | 258.3 | $2.6 | $7,284.7 | $17.3 | $11,242.0 | $18,546.6 |
| Other comprehensive income, net of tax | — | — | — | 5.2 | — | 5.2 |
| Net loss | — | — | — | — | (3,593.6) | (3,593.6) |
| Repurchases of common stock | (0.8) | 0.0 | (315.8) | — | — | (315.8) |
| Common stock withheld for employee tax obligations | (0.1) | 0.0 | (80.5) | — | — | (80.5) |
| Issuance of common stock under benefit plans | 0.6 | 0.0 | 55.8 | — | — | 55.8 |
| Stock-based compensation expense | — | — | 157.0 | — | — | 157.0 |
| Balance at June 30, 2024 | 258.0 | $2.6 | $7,101.2 | $22.5 | $7,648.4 | $14,774.7 |
| Six Months Ended | ||||||
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings · Total Shareholders’ Equity | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2022 | 257.0 | $2.6 | $7,386.5 | $0.8 | $6,522.8 | $13,912.7 |
| Other comprehensive loss, net of tax | — | — | — | (40.6) | — | (40.6) |
| Net income | — | — | — | — | 1,615.5 | 1,615.5 |
| Repurchases of common stock | (0.5) | (0.0) | (161.1) | — | — | (161.1) |
| Common stock withheld for employee tax obligations | (0.6) | (0.0) | (169.7) | — | — | (169.7) |
| Issuance of common stock under benefit plans | 1.9 | 0.0 | 70.7 | — | — | 70.7 |
| Stock-based compensation expense | — | — | 242.7 | — | — | 242.7 |
| Balance at June 30, 2023 | 257.8 | $2.6 | $7,369.1 | $(39.8) | $8,138.3 | $15,470.2 |
| Balance at December 31, 2023 | 257.7 | $2.6 | $7,449.7 | $(14.3) | $10,142.4 | $17,580.4 |
| Other comprehensive income, net of tax | — | — | — | 36.8 | — | 36.8 |
| Net loss | — | — | — | — | (2,494.0) | (2,494.0) |
| Repurchases of common stock | (1.1) | (0.0) | (456.2) | — | — | (456.2) |
| Common stock withheld for employee tax obligations | (0.7) | (0.0) | (314.0) | — | — | (314.0) |
| Issuance of common stock under benefit plans | 2.1 | 0.0 | 71.7 | — | — | 71.7 |
| Stock-based compensation expense | — | — | 350.0 | — | — | 350.0 |
| Balance at June 30, 2024 | 258.0 | $2.6 | $7,101.2 | $22.5 | $7,648.4 | $14,774.7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.